Novo Nordisk to Acquire Dicerna Pharmaceuticals Including the RNAi Research Technology Platform
BAGSVAERD DK – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a… Read More



